Clinical Trial Update: Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD [Phase 3]

View source ↗

Summary

Phase 3 study evaluated the efficacy and safety of canakinumab in Japanese adults with Adult Onset Still's Disease. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adult-onset Still Disease

Drugs mentioned

• Ilaris (canakinumab) (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Adult Onset Still's Disease | Phase 3 | Status: COMPLETED | Results posted: 2026-03-23